Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Opioid

or Research material

or [[:Category:Overactive_bladder_medications|Overactive bladder medication]]

Use the filters below to narrow your results.

Codeine (2)

Other values:

None (140) · (multiple, generic dominant) (1) · (none, never marketed) (1) · Alfenta (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Ditropan, Ditropan XL, Oxytrol (transdermal), Gelnique (gel) (1) · Dolophine (1) · Duragesic (1) · Heroin (1) · Krokodil (1) · Myrbetriq (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Stablon (1) · Stadol (1) · Suboxone (1) · Sufenta (1) · Talwin (1) · Ultiva (1) · Vesicare (1) · Vicodin (1)

5-HT2A agonist (26) · Monoamine releasing agent (9) · GABAA positive allosteric modulator (8) · CB1/CB2 agonist (7) · Potent mu-opioid receptor agonist (6) · Dopamine/norepinephrine reuptake inhibitor (5) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Mu-opioid receptor agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Serotonin/norepinephrine/dopamine releasing agent (3) · None (2) · Cathinone analogue; monoamine reuptake inhibitor (2) · Dopamine and norepinephrine reuptake inhibitor (2) · NMDA antagonist (2) · Prodrug of GHB (2)

Other values:

None (159) · Mild to moderate pain; cough suppression (low-dose). (1) · No approved medical problem. Encountered as a designer/research benzodiazepine and, increasingly, as an adulterant in illicit opioid supplies. (1) · '"`UNIQ--vote-000006DE-QINU`"', '"`UNIQ--vote-000006DF-QINU`"', '"`UNIQ--vote-000006E0-QINU`"' (1) · '"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"' (1) · '"`UNIQ--vote-00000DFC-QINU`"', '"`UNIQ--vote-00000DFD-QINU`"' (1)

None (159) · 25 mg PO once daily; titrate to 50 mg after 4-8 weeks if needed (1) · 5 mg PO once daily; titrate to 10 mg after 2 weeks if needed (1) · Adult: 15–60 mg every 4 hours as needed. (1) · IR 5 mg PO BID-TID; ER 5-10 mg PO daily, titrate; transdermal patch 3.9 mg/d twice weekly (OTC) (1) · No medical dose. Active recreational doses reported in the 0.5–1.5 mg range (similar potency to alprazolam). (1)

None (159) · 25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric) (1) · 5 mg IR tablets; 5, 10, 15 mg ER tablets; 5 mg/5 mL syrup; 3.9 mg/24 h transdermal patch (Oxytrol); 10% topical gel (1) · 5, 10 mg tablets (1) · Illicit tablets ("bars"), powders, blotter, occasionally solutions. No pharmaceutical product exists. (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (159) · 10 mg/d (5 mg if severe renal or moderate hepatic impairment, or strong CYP3A4 inhibitors) (1) · 30 mg/d (XL) typical (1) · 360 mg/day (1) · 50 mg/d (1) · N/A (never approved) (1)

None (159) · intranasal; rectal and IV reported. (1) · intravesical (1) · Oral (4) · PO (only formulation marketed in the US). (1) · sublingual (1) · topical gel (1) · transdermal (1)

None (159) · 30-60 minutes (PO) (1) · 30–60 min (PO) (1) · Symptom improvement within 1-2 weeks (1) · Symptom improvement within weeks (1) · ~20–40 min PO; faster sublingual/intranasal. (1)

None (159) · 24 hours (2) · 4–6 hours (1) · 6–10 h subjective; full pharmacologic effect considerably longer. (1) · IR: 6-10 hours; ER: 24 hours (1)

None (159) · 2-3 hours (parent and active N-desethyl metabolite)'"`UNIQ--ref-000006E1-QINU`"' (1) · 2.5–3 hours (1) · Estimated ~12–17 h (some sources cite up to ~21 h); active metabolites prolong effect. (1) · ~45-68 hours'"`UNIQ--ref-00000DFE-QINU`"' (1) · ~50 hours'"`UNIQ--ref-00000C4E-QINU`"' (1)

None (159) · 25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) · Not formally characterized in humans. (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"' (1) · ~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"' (1)

None (159) · Avoid. Benzodiazepines are associated with neonatal sedation, floppy-infant syndrome, and withdrawal; teratogenic signal weak but non-zero. Designer benzo with no safety data, assume worst-case. (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (3)

None (160) · OTC (transdermal patch in women) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (2)

1

2

3

4

5

7

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

R

S

T

U